Sixth Annual Coalition Against Major Diseases/Food and Drug Administration Scientific Workshop; Public Workshop, 45998-45999 [2015-18969]
Download as PDF
45998
Federal Register / Vol. 80, No. 148 / Monday, August 3, 2015 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
B. Application Cover Sheet Procedures
Food and Drug Administration
Step One—Create a user account and
password. Log on to the ADUFA Web
site at https://www.fda.gov/ForIndustry/
UserFees/
AnimalDrugUserFeeActADUFA/
default.htm and, under Tools and
Resources, click ‘‘The Animal Drug User
Fee Cover Sheet’’ and then click ‘‘Create
ADUFA User Fee Cover Sheet.’’ For
security reasons, each firm submitting
an application will be assigned an
organization identification number, and
each user will also be required to set up
a user account and password the first
time you use this site. Online
instructions will walk you through this
process.
Step Two—Create an Animal Drug
User Cover Sheet, transmit it to FDA,
and print a copy. After logging into your
account with your user name and
password, complete the steps required
to create an Animal Drug User Fee
Cover Sheet. One cover sheet is needed
for each animal drug application or
supplement. Once you are satisfied that
the data on the cover sheet is accurate
and you have finalized the cover sheet,
you will be able to transmit it
electronically to FDA and you will be
able to print a copy of your cover sheet
showing your unique PIN.
Step Three—Send the payment for
your application as described in section
VIII.A.
Step Four—Please submit your
application and a copy of the completed
Animal Drug User Fee Cover Sheet to
the following address: Food and Drug
Administration, Center for Veterinary
Medicine, Document Control Unit
(HFV–199), 7500 Standish Pl.,
Rockville, MD 20855.
[Docket No. FDA–2015–N–0001]
C. Product, Establishment, and Sponsor
Fees
mstockstill on DSK4VPTVN1PROD with NOTICES
within 1 working day, using the PIN
described previously.
Jacqueline Brooks-Leighton, Food and
Drug Administration, Center for Drug
Evaluation and Research, 10903 New
Hampshire Ave., Bldg. 21, Rm. 4521,
Silver Spring, MD 20993, 240–402–
5292, FAX: 301–796–9907,
jacqueline.brooks-leighton@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
By December 31, 2015, FDA will issue
invoices and payment instructions for
product, establishment, and sponsor
fees for FY 2016 using this fee schedule.
Payment will be due by January 31,
2016. FDA will issue invoices in
November 2016 for any products,
establishments, and sponsors subject to
fees for FY 2016 that qualify for fees
after the December 2015 billing.
Dated: July 28, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–18913 Filed 7–31–15; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
18:35 Jul 31, 2015
Jkt 235001
Sixth Annual Coalition Against Major
Diseases/Food and Drug
Administration Scientific Workshop;
Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration (FDA) is announcing the
sixth annual scientific workshop cosponsored by the Agency and the
Coalition Against Major Diseases
(CAMD) Consortium of the Critical Path
Institute (C-Path). The purpose of this
public workshop is to initiate
constructive discussion among
scientists from FDA, the CAMD
Consortium, and other interested parties
regarding ongoing efforts to develop
tools and methods to facilitate drug
development for Alzheimer’s disease
and Parkinson’s disease.
DATES: The public scientific workshop
will be held on October 15, 2015, from
8 a.m. to 5 p.m.
ADDRESSES: The public workshop will
be held at the FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503A), Silver Spring, MD 20993–0002.
Entrance for the public scientific
workshop participants (non-FDA
employees) is through Building 1, where
routine security check procedures will
be performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
SUMMARY:
community, patient advocacy groups,
and governmental institutions;
including, the National Institute of
Aging, the National Institute of
Neurological Disorders and Stroke, and
the European Medicines Agency.
The objectives of the workshop
include:
1. Understanding the accomplishments
of CAMD scientific projects
2. Discussing how these tools are
currently or will be applied in drug
development
3. Obtaining commitment for sharing
information/data to begin
quantifying benefits of these tools
4. Facilitating robust and open
discussion among all parties of drug
development in Alzheimer’s and
Parkinson’s diseases
I. Background
II. Attendance and Registration
The FDA Conference Center at the
White Oak location is a Federal facility
with security procedures and limited
seating. Individuals who wish to
participate in the scientific workshop
(in person or via the Internet) must
register on or before October 1, 2015, by
visiting https://www.SignUp4.net/
public/ap.aspx?EID=SIXT10E.
Early registration is recommended;
registration is free and will be on a firstcome, first-served basis. However, FDA
may limit the number of participants
from each organization based on space
limitations. Onsite registration on the
day of the scientific workshop will be
based on space availability. The
registration deadline is October 14,
2015. An agenda will be provided
approximately 2 weeks before the
scientific workshop at the FDA Meeting
Information page, which is available
online at: https://www.fda.gov/Drugs/
NewsEvents/ucm410863.htm.
If you need special accommodations
because of a disability, please contact
Jacqueline Brooks-Leighton (see FOR
FURTHER INFORMATION CONTACT) at least 7
days before the scientific workshop.
A live webcast of this scientific
workshop will be viewable at Adobe
Connect Link: https://
collaboration.fda.gov/camd101515/ on
the day of the scientific workshop. A
video record of the scientific workshop
will be available at the same Web
address for 1 year.
FDA and C-Path seek to leverage their
combined strengths to create new tools
and methods to increase the efficiency
of the drug development process and
bring new treatments for Alzheimer’s
disease and Parkinson’s disease. This
annual public workshop brings together
representatives from the pharmaceutical
industry, the academic research
III. Transcripts
Please be advised that as soon as a
transcript is available, it will be
accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. A transcript
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
E:\FR\FM\03AUN1.SGM
03AUN1
Federal Register / Vol. 80, No. 148 / Monday, August 3, 2015 / Notices
will also be available in either hard
copy or on CD–ROM, after submission
of a Freedom of Information request.
Written requests are to be sent to
Division of Freedom of Information
(ELEM–1029), Food and Drug
Administration, 12420 Parklawn Dr.,
Element Bldg., Rockville, MD 20857.
Dated: July 29, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–18969 Filed 7–31–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2015–N–0001]
Surrogate Endpoints for Clinical Trials
in Kidney Transplantation; Public
Workshop
Food and Drug Administration,
HHS.
mstockstill on DSK4VPTVN1PROD with NOTICES
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA) is announcing a public workshop
entitled ‘‘Surrogate Endpoints for
Clinical Trials in Kidney
Transplantation.’’ The purpose of the
public workshop is to discuss potential
surrogate endpoints for clinical trials for
drugs and therapeutic biologics used in
kidney transplantation, with a focus on
endpoints in conditions that represent
unmet medical needs. This public
workshop is intended to provide
information and gain perspective from
health care providers, academia, and
industry on the role of various
laboratory, histologic, and other
endpoints used to evaluate patient and
allograft outcome in clinical trials for
kidney transplantation.
Date and Time: The public workshop
will be held on September 28, 2015,
from 8 a.m. to 6 p.m.
Location: The public workshop will
be held at the Residence Inn Marriott,
2850 South Potomac Ave., Arlington,
VA 22202. Web site: https://
www.marriott.com/hotels/travel/wasryresidence-inn-arlington-capital-view/.
(FDA has verified the Web site address,
but FDA is not responsible for any
subsequent changes to the Web site after
this document publishes in the Federal
Register.) Seating will be available on a
first-come, first-served basis.
Contact Person: Ramou Pratt, Center
for Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 6193,
Silver Spring, MD 20993–0002, 301–
796–3928 or 301–796–1600.
VerDate Sep<11>2014
18:35 Jul 31, 2015
Jkt 235001
FDA is
announcing a public workshop entitled
‘‘Surrogate Endpoints for Clinical Trials
in Kidney Transplantation.’’ The
purpose of the workshop is to discuss
potential clinical or surrogate endpoints
and biomarkers for clinical trials for
drugs and therapeutic biologics in
kidney transplantation. The input from
this public workshop will help in
developing topics for further discussion
and may serve to inform
recommendations on potential surrogate
endpoints in clinical trials for kidney
transplantation. The Agency encourages
individuals, patient advocates, industry,
consumer groups, health care
professionals, researchers, and other
interested persons to attend this public
workshop.
This workshop is part of the Agency’s
program to facilitate the development of
surrogate endpoints, clinical endpoints,
and other scientific methods for
predicting clinical benefit, in
accordance with section 901 of the Food
and Drug Administration Safety and
Innovation Act, titled ‘‘Enhancement of
Accelerated Patient Access to New
Medical Treatments,’’ which was signed
into law on July 9, 2012. During the
workshop, there will be a discussion on
potential surrogate endpoints and their
ability to predict clinical benefit.
This public workshop will include
discussion of allograft histology and
biomarkers, laboratory measures of
outcome, and other endpoints that may
serve as surrogates for patient
morbidity, graft function, and patient
and graft survival. Related topics for
discussion will include clinically
relevant risk factors and prognostic
factors in the kidney transplant
population. Patient selection and
enrichment strategies (inclusion/
exclusion criteria) will be considered.
The public workshop will include
scientific discussion on the following
topics:
SUPPLEMENTARY INFORMATION:
Food and Drug Administration
AGENCY:
Registration: Mail or fax your
registration information (including
name, title, firm name, address,
telephone and fax numbers) to Ramou
Pratt (see Contact Person) by September
25, 2015. Registration is free for the
public workshop. Early registration is
recommended because seating is
limited. Registration on the day of the
public workshop will be provided on a
space-available basis beginning at 8 a.m.
If you need special accommodations
because of a disability, please contact
Ramou Pratt (see Contact Person) at
least 7 days in advance.
• Surrogate endpoints and accelerated
approval
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
45999
• Unmet medical need in kidney
transplant patients
• Histology: Findings on kidney biopsy
(including protocol biopsies)
• Laboratory measurements and
outcomes, surrogates and biomarkers
• Patient selection criteria and
enrichment strategies
• Risk factors and prognostic factors
• Medication adherence
Transcripts: Please be advised that as
soon as possible after a transcript of the
public workshop is available, it will be
accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. A transcript
will also be available in either hard
copy or on CD–ROM, after submission
of a Freedom of Information request.
Send written requests to the Division of
Freedom of Information, U.S. Food &
Drug Administration, 5630 Fishers
Lane, Rm. 1033, Rockville, MD 20857.
Transcripts will also be available on the
Internet at https://wcms.fda.gov/FDAgov/
Drugs/NewsEvents/ucm449248.htm
approximately 45 days after the
workshop.
Dated: July 29, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–18957 Filed 7–31–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–D–2138]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Guidance for
Industry on Adverse Event Reporting
for Outsourcing Facilities Under
Section 503B of the Federal Food,
Drug, and Cosmetic Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by September
2, 2015.
SUMMARY:
E:\FR\FM\03AUN1.SGM
03AUN1
Agencies
[Federal Register Volume 80, Number 148 (Monday, August 3, 2015)]
[Notices]
[Pages 45998-45999]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18969]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-0001]
Sixth Annual Coalition Against Major Diseases/Food and Drug
Administration Scientific Workshop; Public Workshop
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the sixth
annual scientific workshop co-sponsored by the Agency and the Coalition
Against Major Diseases (CAMD) Consortium of the Critical Path Institute
(C-Path). The purpose of this public workshop is to initiate
constructive discussion among scientists from FDA, the CAMD Consortium,
and other interested parties regarding ongoing efforts to develop tools
and methods to facilitate drug development for Alzheimer's disease and
Parkinson's disease.
DATES: The public scientific workshop will be held on October 15, 2015,
from 8 a.m. to 5 p.m.
ADDRESSES: The public workshop will be held at the FDA White Oak
Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great
Room (Rm. 1503A), Silver Spring, MD 20993-0002. Entrance for the public
scientific workshop participants (non-FDA employees) is through
Building 1, where routine security check procedures will be performed.
For parking and security information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
FOR FURTHER INFORMATION CONTACT: Jacqueline Brooks-Leighton, Food and
Drug Administration, Center for Drug Evaluation and Research, 10903 New
Hampshire Ave., Bldg. 21, Rm. 4521, Silver Spring, MD 20993, 240-402-
5292, FAX: 301-796-9907, jacqueline.brooks-leighton@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA and C-Path seek to leverage their combined strengths to create
new tools and methods to increase the efficiency of the drug
development process and bring new treatments for Alzheimer's disease
and Parkinson's disease. This annual public workshop brings together
representatives from the pharmaceutical industry, the academic research
community, patient advocacy groups, and governmental institutions;
including, the National Institute of Aging, the National Institute of
Neurological Disorders and Stroke, and the European Medicines Agency.
The objectives of the workshop include:
1. Understanding the accomplishments of CAMD scientific projects
2. Discussing how these tools are currently or will be applied in drug
development
3. Obtaining commitment for sharing information/data to begin
quantifying benefits of these tools
4. Facilitating robust and open discussion among all parties of drug
development in Alzheimer's and Parkinson's diseases
II. Attendance and Registration
The FDA Conference Center at the White Oak location is a Federal
facility with security procedures and limited seating. Individuals who
wish to participate in the scientific workshop (in person or via the
Internet) must register on or before October 1, 2015, by visiting
https://www.SignUp4.net/public/ap.aspx?EID=SIXT10E.
Early registration is recommended; registration is free and will be
on a first-come, first-served basis. However, FDA may limit the number
of participants from each organization based on space limitations.
Onsite registration on the day of the scientific workshop will be based
on space availability. The registration deadline is October 14, 2015.
An agenda will be provided approximately 2 weeks before the scientific
workshop at the FDA Meeting Information page, which is available online
at: https://www.fda.gov/Drugs/NewsEvents/ucm410863.htm.
If you need special accommodations because of a disability, please
contact Jacqueline Brooks-Leighton (see FOR FURTHER INFORMATION
CONTACT) at least 7 days before the scientific workshop.
A live webcast of this scientific workshop will be viewable at
Adobe Connect Link: https://collaboration.fda.gov/camd101515/ on the
day of the scientific workshop. A video record of the scientific
workshop will be available at the same Web address for 1 year.
III. Transcripts
Please be advised that as soon as a transcript is available, it
will be accessible at https://www.regulations.gov. It may be viewed at
the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. A
transcript
[[Page 45999]]
will also be available in either hard copy or on CD-ROM, after
submission of a Freedom of Information request. Written requests are to
be sent to Division of Freedom of Information (ELEM-1029), Food and
Drug Administration, 12420 Parklawn Dr., Element Bldg., Rockville, MD
20857.
Dated: July 29, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-18969 Filed 7-31-15; 8:45 am]
BILLING CODE 4164-01-P